University of Washington Arboviral Research Network (UWARN)

摘要：华盛顿大学树状病毒研究网络(UWARN) 华盛顿大学树状病毒研究网络(UWARN)将研究新兴和重新出现的病毒 通过对虫媒病毒进行研究，包括目前高负担的病原体，包括 登革热、基孔肯雅热和寨卡病毒。虫媒病毒还包括新出现和重新出现的病毒，如 Mayaro、Una、Usutu、日本脑炎、黄热病、克里米亚-刚果出血热和Oropouche 病毒。UWARN将利用UW大流行疾病准备和强有力的研究中心 在巴西、塞内加尔、南非、巴基斯坦和台湾的实验室合作伙伴以及威斯康星大学 全球卫生在能力建设方面的全球影响。UWARN国际合作伙伴拥有 基于机构和基于人口的队列到位，以执行计划的研究和监测新的 病毒出现了。拟议的UWARN研究将创造新的人类病毒中和单克隆 可用于治疗或诊断的抗体(Hu-nMab)。UWARN的研究也将创造新的 诊断学，由蛋白质设计研究所从头开始创造，作为人造蛋白质，当 病毒抗体存在于体液中。最后，UWARN的研究将产生对如何 病毒操纵人类的先天免疫系统，这些信息将被用来设计生物标记物来 预测严重疾病，并建议宿主指导的治疗方案，这些疗法可能会导致更好的结果 虫媒病毒感染。建议的技术是通用的，可以迅速适应未来的任何新兴技术 虫媒病毒威胁。UWARN的合作者横跨病毒学、细菌学、真菌学和寄生虫感染，因此 UWARN可以应对各种新出现的传染病威胁。UWARN国际实验室已经 高级功能，包括带发电机-电源备份-80C冷冻机的生物储存库，下一代 测序(NGS)能力、荧光细胞分类和BSL-3遏制设施。UWARN的同龄人 在急性发热性疾病期间从患有已知和未知虫媒病毒的个人身上采集的生物库样本 疾病监测中心和伙伴关系地点已准备好收集人口样本和设施样本。 UWARN实验室将使用元基因组NGS来检测附属队列中出现的新病毒。UWARN合作伙伴 有合作的昆虫学家和兽医对节肢动物病媒和动物宿主进行采样 需要的。其他创新能力包括巴西UWARN合作伙伴的车载NGS移动面包车 能够在不到18小时的时间内对病毒进行实时、现场测序和采样，以进行病毒识别。一秒钟 合作伙伴，塞内加尔的IRESSEF，计划建立一个类似的移动工具，用于病毒采样和测序 塞内加尔和巴西集团将在技术转让和最佳做法方面与IRESSEF合作。UWARN 合作伙伴将作为其他新兴传染病研究中心(EIDRC)的资源，提供 在单抗、蛋白质设计和宿主导向疗法方面的专业知识。

Abstract: University of Washington Arboviral Research Network (UWARN) The University of Washington Arboviral Research Network (UWARN) will address emerging and re-emerging infectious diseases by carrying out research on arboviruses that include current high burden pathogens including dengue, chikungunya, and Zika viruses. Arboviruses also include emerging and re-emerging viruses such as Mayaro, Una, Usutu, Japanese encephalitis, yellow fever, Crimean-Congo hemorrhagic fever, and Oropouche viruses. UWARN will leverage the UW Metacenter for Pandemic Disease Preparedness and strong research laboratory partners in Brazil, Senegal, South Africa, Pakistan and Taiwan as well as the UW Department of Global Health global reach in capacity building. The UWARN international Collaborating Partners have institution-based and population-based cohorts in place to carry out the planned research and monitor for new virus emergence. The proposed UWARN research will create new human viral-neutralizing monoclonal antibodies (Hu-nMabs) that can be used as therapeutics or diagnostics. UWARN research will also create new diagnostics, created ab initio by the Institute for Protein Design, as artificial proteins that release light when antibodies to virus are present in body fluids. Finally, UWARN research will generate an understanding of how viruses manipulate the human innate immune system, and this information will be used to design biomarkers to predict severe disease as well as to suggest host-directed therapies that could lead to better outcomes after arboviral infection. The proposed technologies are generic and could be rapidly adapted to any future emerging arbovirus threat. UWARN collaborators span virology, bacteriology, mycology, and parasitic infections, such that UWARN can respond to diverse emerging infectious diseases threats. UWARN international laboratories have advanced capabilities including biorepositories with generator-power backed-up -80C freezers, next-generation sequencing (NGS) capabilities, fluorescence cell sorting, and BSL-3 containment facilities. UWARN cohorts have biobanked samples taken from individuals during acute febrile illnesses, with known and unknown arboviral diseases, and partnership sites are poised for prospective collection of population and facility–based samples. UWARN labs will use metagenomic NGS to detect novel viral emergence in affiliated cohorts. UWARN Partners have collaborating entomologists and veterinarians to sample arthropod vectors and animal reservoirs as needed. Additional innovative capacity included the Brazil UWARN partner’s mobile van with on board NGS capability for real-time, on-site viral sequencing and sampling to viral identification in less than 18 hrs. A second partner, IRESSEF in Senegal, plans to set up a similar mobile vehicle for viral sampling and sequencing in Senegal and the Brazil group will collaborate with IRESSEF on technology transfer and best practices. UWARN partners will serve as a resource to other Emerging Infectious Diseases Research Centers (EIDRC) providing expertise in monoclonal antibodies, protein design, and host directed therapies.